[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370282-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-370282-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","gata3-amplification-is-associated-with-high-grade-disease-in-non-invasive-urothelial-bladder-cancer-but-unrelated-to-patient-prognosis","GATA3 amplification is associated with high grade disease in non-invasive urothelial bladder cancer but unrelated to patient prognosis","","The study evaluates how GATA3 (GATA binding protein 3) gene copy number alterations affect tumor aggressiveness, patient prognosis, and GATA3 protein expression in a large urothelial bladder cancer cohort. A retrospective analysis used a tissue microarray of over 2,700 tumors and dual-labeling fluorescence in situ hybridization (FISH) to measure GATA3 copy gains and deletions. High-level amplification was frequent, increased across pTa grades, and related to grade progression in non-muscle-invasive disease, while links to aggressiveness or survival were not observed for muscle-invasive cancers.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/gata3-amplification-is-associated-with-high-grade-disease-in-non-invasive-urothelial-bladder-cancer-but-unrelated-to-patient-prognosis/370282/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/gata3-amplification-is-associated-with-high-grade-disease-in-non-invasive-urothelial-bladder-cancer-but-unrelated-to-patient-prognosis/370282.png","ImageObject",300,407,{"name":42,"@type":43},"Liam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study’s main purpose regarding GATA3?","Question",{"text":63,"@type":64},"To assess how GATA3 gene copy number alterations influence tumor aggressiveness, patient prognosis, and GATA3 protein expression in a large urothelial bladder cancer cohort.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were GATA3 copy number alterations measured?",{"text":68,"@type":64},"Through retrospective analysis of a tissue microarray using dual-labeling fluorescence in situ hybridization (FISH) with probes for GATA3 and centromere 10, with gains and deletions categorized by ratio thresholds.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the results show about high-level GATA3 amplification?",{"text":72,"@type":64},"High-level amplification increased with progression among pTa tumors and was common in urothelial bladder cancer, but in muscle-invasive carcinomas it was not linked to tumor aggressiveness or patient survival.",{"name":74,"@type":61,"acceptedAnswer":75},"How did GATA3 deletion relate to cancer progression?",{"text":76,"@type":64},"No homozygous GATA3 deletion was detected, and heterozygous deletion was rare and not associated with cancer progression in the analyzed subset.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},370282,1790219198,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":147,"read_time":122,"preview_page_count":33,"preview_urls":148},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Plage et al. BMC Urology (2025) 25:37 [https://doi.org/10.1186/s12894-025-01704-y](https://doi.org/10.1186/s12894-025-01704-y)  \nBMC Urology  \nRESEARCH Open Access  \nGATA3 amplification is associated with high grade disease in non-invasive urothelial bladder cancer but unrelated to patient prognosis  \nHenning Plage 1*, Adrian Frericks2, Sebastian Hofbauer 1, Kira Furlano 1, Sarah Weinberger 1, Florian Roßner3, Simon Schallenberg3, Sefer Elezkurtaj3, Maximilian Lennartz2, Andreas Marx4, Henrik Samtleben4, Margit Fisch5, Michael Rink6, Marcin Slojewski7, Krystian Kaczmarek7, Thorsten Ecke8, Stefan Koch9, Ronald Simon2, Guido Sauter2, Henrik Zecha 10, Joachim Weischenfeldt 1,11, Tobias Klatte8, Sarah Minner2, David Horst3, Thorsten Schlomm 1 and Martina Kluth2  \nAbstract  \nPurpose We aimed to assess the impact of GATA3 binding protein (GATA3) gene copy number alterations on tumor aggressiveness, patient prognosis, and GATA3 protein expression in a large urothelial bladder cancer cohort.  \nMethods A tissue microarray containing over 2,700 urothelial bladder cancers (pTa-pT4) was analyzed retrospectively using dual-labeling fluorescence in-situ hybridization (FISH) with probes for GATA3 (10p14) and centromere 10. GATA3 copy number gains were categorized as GATA3 elevation (ratio GATA3/centromere ≥ 2/≤4), low-level amplification (ratio > 4/≤12), and high-level amplification (ratio > 12) and deletions were divided between homozygous and heterozygous.  \nResults GATA3 copy number gain was detected in 9. 9% of 2,213 interpretable tumors, including 2. 0% with GATA3 elevation, 3. 2% with low-level amplification, and 4. 7% with high-level amplification. The frequency of high-level amplification increased from pTa G2 low (0%) to pTa G3 tumors (12%[CI 0. 07;0 . 21]; p \u003C 0.0001 pTa G2 low vs. pTaG2 high) but decreased in advanced-stage carcinomas pT2-4 with 5.4%[CI 0. 07;0 . 21](p \u003C 0. 0001, pTa vs. pT2-4) . In muscle-invasive carcinomas, GATA3 amplification was not linked to tumor aggressiveness or patient survival. Overall, no homozygous GATA3 deletion was detected and heterozygous GATA3 deletion was only observed in 1. 1%; of 1,432 pT2-4 tumors without any association to cancer progression. While GATA3 copy number was significantly correlated with GATA3 expression (p \u003C 0. 0001), the relationship was not strong. Only 2. 3% of GATA3-negative cancers had a deletion, and 42 . 1% of strong GATA3-expressing cancers exhibited high-level amplification.  \n*Correspondence: Henning Plage [henning.plage@charite.de](henning.plage@charite.de)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/.  \nPlage et al. BMC Urology (2025) 25:37 Page 2 of 8  \nConclusion High-level GATA3 amplification is common in urothelial bladder cancer and correlates with grade progression in pTa tumors, while GATA3 deletion is rare. Neither amplification nor deletion appears to be the primary driver of GATA3 expression dysregulation.  \nClinical trial number Not applicable.  \nKeywords GATA3, Urothelial bladder cancer, FISH, Prognosis  \nIntroduction  \nGATA binding protei","cbCaiiPMaiyyfWqc","https://ap.wps.com/l/cbCaiiPMaiyyfWqc","pdf",2137617,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What was the study’s main purpose regarding GATA3?\",\"answer\":\"To assess how GATA3 gene copy number alterations influence tumor aggressiveness, patient prognosis, and GATA3 protein expression in a large urothelial bladder cancer cohort.\"},{\"question\":\"How were GATA3 copy number alterations measured?\",\"answer\":\"Through retrospective analysis of a tissue microarray using dual-labeling fluorescence in situ hybridization (FISH) with probes for GATA3 and centromere 10, with gains and deletions categorized by ratio thresholds.\"},{\"question\":\"What did the results show about high-level GATA3 amplification?\",\"answer\":\"High-level amplification increased with progression among pTa tumors and was common in urothelial bladder cancer, but in muscle-invasive carcinomas it was not linked to tumor aggressiveness or patient survival.\"},{\"question\":\"How did GATA3 deletion relate to cancer progression?\",\"answer\":\"No homozygous GATA3 deletion was detected, and heterozygous deletion was rare and not associated with cancer progression in the analyzed subset.\"}]","GATA3 amplification is associated with high grade disease in non-invasive urothelial bladder cancer but unrelated to patient prognosis | PDF",1790187738,[149,153,157,161],{"page_no":22,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce29c044fee47aa7297e72cd29d048ed.webp",983,1310,{"page_no":26,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ffde4ce468c338d5e418524b1c2cf11f.webp",982,1309,{"page_no":30,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe3624e59ed1ad5eef193c022bd5e633.webp",981,1308,{"page_no":33,"url":162,"width":163,"height":164},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a08b11e675948080689c77168d3d2397.webp",980,1306]